RecallRadar

FDA Drug recall D-0402-2025

Ropivacaine Hydrochloride Injection, USP, 0.5%, 500 mg per 100 mL (5mg/mL), Manufactured by: Amneal Pharmaceuticals Pvt

On 2025-05-14 the FDA classified a Class I recall of Ropivacaine Hydrochloride Injection, USP, 0.5%, 500 mg per 100 mL (5mg/mL), Manufactured by: Amneal Pharmaceuticals Pvt by Amneal Pharmaceuticals, citing presence of Particulate Matter.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0402-2025
ClassificationClass I
Statusongoing
Initiated2025-04-17
Published2025-05-14
Last updated2026-09-13 11:52 UTC
CompanyAmneal Pharmaceuticals
DistributionUS

Product

Ropivacaine Hydrochloride Injection, USP, 0.5%, 500 mg per 100 mL (5mg/mL), Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Mehsana, India, , Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807 NDC 70121-1734-1 (bag); NDC 70121-1734-3 (box)

Reason

Presence of Particulate Matter

Identifiers

ndc70121-1732-9
ndc70121-1732-3
ndc70121-1733-9
ndc70121-1733-3
ndc70121-1734-7
ndc70121-1734-3
ndc70121-1735-7
ndc70121-1735-3
ndc70121-1734-1
code_infoLot #'s: AL240003, AL240004, Exp.: 01/31/2026

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0402-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.